Novo’s Fight Against Copycat Obesity Drugs

Novo Nordisk slashes its 2025 forecast but surges 6.5% as it vows to crush copycat obesity drugs. Will Wegovy reclaim...

07/05/2025

1 views

Hims & Hers Soars With Novo Nordisk Wegovy Deal

Hims & Hers stock skyrockets 27% with Novo Nordisk's Wegovy deal. What’s driving this telehealth surge, and is it time...

29/04/2025

0 views

Novo Nordisk's legal victory limits compounded Wegovy and Ozempic. What does this mean for patients seeking affordable options? Click to...

25/04/2025

0 views